Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2025-12-25 @ 4:08 AM
NCT ID:
NCT00234520
Eligibility Criteria:
Inclusion Criteria:
* Patient has a diagnosis of Acromegaly
* Patient is being treated with lanreotide or octreotide in any dose form at the selection visit or is a de novo patient who is due to commence treatment within 2 weeks of baseline
* Patient started treatment with either lanreotide or octreotide when both products were available on the market in their country
* Patient must not change treatment form lanreotide to octreotide or vice versa for the duration of the study
Exclusion Criteria:
* Patients with known significant valve abnormalities prior to treatment with either lanreotide or octreotide
* Patients who have received treatment with a somatostatin analogue other than lanreotide or octreotide for more than 3 months
* Patients who have received treatment with a GH antagonist for more than 3 months
* Patients who have had heart valve replacement therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00234520
Study Brief:
Protocol Section:
NCT00234520